Suzhou Genhouse Bio Co. Ltd. has prepared and tested new histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, asthma, Alzheimer’s diseases, diabetes, amyotrophic lateral sclerosis, multiple sclerosis, pulmonary fibrosis and psoriasis, among others.
Oryzon Genomics SA has nominated ORY-4001, a selective histone deacetylase 6 (HDAC6) inhibitor, as a clinical development candidate for the treatment of certain neurological diseases, including Charcot-Marie-Tooth (CMT), amyotrophic lateral sclerosis (ALS) and others.
Genhouse Medicine (Suzhou) Co. Ltd. has divulged histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer, idiopathic thrombocytopenic purpura, rheumatoid arthritis, diabetes, multiple sclerosis, lung, alcoholic liver and Alzheimer's diseases, among others.
Researchers from Ocean University of China, Qingdao National Laboratory for Marine Science and Technology and affiliated organizations have reported the discovery of novel histone deacetylase 6 (HDAC6) inhibitors as potential anti-inflammatory agents.
Researchers from Italfarmaco SpA presented a new class of highly selective histone deacetylase 6 (HDAC6) inhibitors as potential candidates for the treatment of several pathologies, such as autoimmune disorders, neurodegenerative diseases, and cancer.
Eikonizo Therapeutics Inc. has identified histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders, among others.
